FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12014037126412/18/14 new patent  Muscarinic acetylcholine receptor antagonists
22014033508311/13/14Methods of treatment and prevention of eye diseases
32014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
42014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
52014022725908/14/14Modified proteins and peptides
62014022726408/14/14Drug fusions and conjugates with extended half life
72014020560407/24/14Antigen binding constructs
82014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
92014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
102014019340707/10/14Drug fusions and conjugates
112014018775007/03/14Methods for selecting protease resistant polypeptides
122014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
132014015870406/12/14Medicament dispenser
142014014099605/22/14Anti-serum albumin biding variable domains
152014011643405/01/14Dry powder inhaler compositions
162014011292904/24/14Tumour necrosis factor receptor 1 antagonists
172014011388804/24/14Novel combination of therapeutic agents
182014011392204/24/14Compounds
192014010589404/17/14Humanized anti-il-18 antibodies
202014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
212014007631403/20/14Manifold for use in medicament dispenser
222014008086303/20/14Muscarinic acetylcholine receptor antagonists
232014005690002/27/14Method for inhibiting binding to b-cell receptor
242014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
252014005071902/20/14Antibodies
262014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
272014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
282014002359601/23/14Novel composition
292014002455801/23/14Method of treatment
302014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
312014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
322013034546512/26/13Process for the preparation of retigabine
332013033698912/19/13Methods of identifying a patient population
342013031590111/28/13Novel uses
352013031704111/28/13Compounds
362013031028111/21/13Novel antigen binding proteins
372013030233511/14/13Ligands that bind tgf-beta receptor ii
382013026771710/10/13Process for the preparation of atovaquone
392013026118510/03/13Benzamide derivatives as ep4 receptor agonists
402013025172409/26/13Antigen binding proteins to oncostatin m (osm)
412013025318809/26/13Novel compounds
422013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
432013022420408/29/13Method of treatment based on atad2 inhibitors
442013021315408/22/13Method of determining cleanliness
452013021339408/22/13Dispensing device
462013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
472013021089208/15/13Method of treatment
482013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
492013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
502013019641208/01/13Magi polynucleotides, polypetides, and antibodies
512013018925507/25/13Fusions and conjugates of insulinotropic agents
522013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
532013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
542013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
552013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
562013007819803/28/13Novel use
572013005337502/28/13Amino-quinolines as kinase inhibitors
582013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
592013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
602013003001201/31/13Compounds
612013003001501/31/13Muscarinic acetylcholine receptor antagonists
622013002354101/24/13Voltage-gated sodium channel blockers
632013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
642012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
652012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
662012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
672012028854411/15/12Novel retigabine composition
682012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
692012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
702012024074209/27/12Novel device
712012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
722012023855909/20/12Novel compounds
732012023857109/20/12Indazole derivatives as pi 3-kinase
742012023206109/13/12Novel compounds
752012020774908/16/12Dosing regimen
762012020281108/09/12Novel compounds
772012015744606/21/12Medical use
782012015749106/21/12Muscarinic acetylcholine receptor antagonists
792012015749206/21/12Antibiotic drug
802012014971106/14/12Piperidine derivatives used as orexin antagonists
812012014973106/14/12New medical use
822012012868905/24/12Anti-il-23 immunoglobulins
832012012977805/24/12Ligand that bind tgf-beta receptor rii
842012011464705/10/12Anti-serum album single variable domains
852012010013704/26/12Immunoglobulins
862012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
872012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
882012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
892012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
902012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
912012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
922012005896303/08/12Macrolides with anti-inflammatory activity
932012004625802/23/12Novel crystalline pharmaceutical product
942012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
952012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
962012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
972012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
982012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
992012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1002012000632201/12/12Drug dispenser
1012012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1022011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1032011030569212/15/11Antigen-binding contructs
1042011030569312/15/11Anitigen-binding constructs
1052011028809811/24/11Novel compounds
1062011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1072011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1082011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1092011026973811/03/11Compounds
1102011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1112011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1122011025375210/20/11Nozzle for a nasal inhaler
1132011025607410/20/11Novel use
1142011024547010/06/11Immunoglobulins
1152011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1162011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1172011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1182011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1192011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1202011015226206/23/11Novel compounds
1212011014282406/16/11Antibodies against amyloid-beta peptide
1222011014415106/16/11Novel process, salts, composition and use
1232011013569506/09/11Oral dosage form for controlled drug release
1242011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1252011011719005/19/11Pharmaceutical formulations
1262011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1272011006164603/17/11Drug dispenser
1282011006474003/17/11Antigen binding proteins
1292011006572503/17/11Triazole amide derivatives for use in therapy
1302011005916703/10/11Encapsulation of biologically active agents
1312011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1322011004502702/24/11Adjuvant
1332011004613702/24/11Pyrazole derivatives as p2x7 modulators
1342011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1352011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1362011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1372011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1382010032999612/30/10Novel combination of therapeutic agents
1392010032402212/23/10Novel compounds
1402010031657912/16/10Novel use of alkyl phosphate esters
1412010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1422010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1432010030808212/09/10Dispensing device
1442010031170612/09/10Method of treatment of allergic rhinitis
1452010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1462010030382112/02/10Immunoglobulins
1472010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1482010030512712/02/10Novel compounds
1492010030516612/02/10Novel compounds
1502010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1512010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1522010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1532010027590911/04/10Actuator for an inhaler
1542010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1552010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1562010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1572010025619910/07/10Crystalline form of an antimalarial compound
1582010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1592010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1602010022418509/09/10Actuator for an inhaler
1612010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1622010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1632010021683708/26/10Glycine transport inhibitors
1642010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1652010020325608/12/10The application of powder material to substrates
1662010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1672010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1682010019767908/05/10Compounds
1692010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1702010019076407/29/10Novel compounds
1712010018477007/22/10Compounds
1722010018499607/22/10Process of amide formation
1732010017569807/15/10Capsule
1742010017406507/08/10Compounds
1752010014809106/17/10Rapid phase luminescense spectroscopy analysis
1762010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1772010014401606/10/10Apparatus for the disruption of animal cells
1782010014475506/10/10Novel compounds
1792010014482906/10/10Novel receptor antagonists and their methods of use
1802010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1812010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1822010013735306/03/10Tricyclic compounds as antibacterials
1832010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1842010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1852010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1862010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1872010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
1882010011379605/06/10Indole derivatives as s1p1 receptor
1892010010565204/29/10Purines as cysteine protease inhibitors
1902010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
1912010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
1922010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
1932010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
1942010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
1952010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
1962010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
1972010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
1982010006816603/18/10Oral composition comprising dimethicone copolyol
1992010006940903/18/10"novel compounds"
2002010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2012010005905203/11/10Sheet driver for use in a drug dispenser
2022010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2032010005650203/04/10Compounds
2042010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2052010005659503/04/10Pyrazole derivatives as p2x7 modulators
2062010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2072010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2082010002969902/04/10Matrix metalloproteinase inhibitors
2092010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2102010001637101/21/10Indole compounds
2112010001002101/14/10Novel compounds
2122010000052801/07/10Manifold for use in medicament dispenser
2132010000052901/07/10Manifold for use in medicament dispenser
2142010000342001/07/10Medicament dispenser
2152010000423001/07/10Azatricyclic compounds and their use
2162010000424001/07/10Indole compounds
2172009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2182009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2192009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2202009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2212009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2222009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2232009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2242009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2252009029874212/03/09Process for manufacturing lactose
2262009029114611/26/09Process for manufacturing lactose
2272009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2282009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2292009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2302009027035510/29/09Compounds
2312009027051010/29/09Glycine transport inhibitors
2322009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2332009023644509/24/09Fluid dispenser
2342009023984609/24/09Novel compounds
2352009023284709/17/09Immunogenic compositions
2362009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2372009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof
2382009022157709/03/09Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
2392009021120108/27/09Apparatus and method for printing packaging elements
2402009020947208/20/09Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents
2412009020365708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2422009020367708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2432009019787108/06/09Dual pharmacophores - pde4-muscarinic antagonistics
2442009019792808/06/09Novel receptor antagonists and their methods of use
2452009018849107/30/09Medicaments
2462009018849207/30/09Canisters for use in metered dose inhalers
2472009019216007/30/09Compounds
2482009018686707/23/09Substituted diketopiperazines as oxytocin antagonists
2492009017867307/16/09Actuation indicator for a dispensing device


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         



Key IP Translations - Patent Translations